Does Brintellix Bring Anything New?
The Carlat Psychiatry Report, Volume 11, Number 11, November 2013
https://www.thecarlatreport.com/newsletter-issue/tcprv11n11/
Issue Links: Learning Objectives | Editorial Information
Topics: Antidepressants | Depressive Disorder
Steve Balt, MD
Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center
Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb.
After a dry spell of new antidepressants—the last one to be approved was levomilnacipran (Fetzima), the active enantiomer of milnacipran (Savella) in July 2013—the FDA approved vortioxetine (Brintellix) in September. Vortioxetine is another serotonergic antidepressant. How exactly does it work, and what are its advantages over existing drugs?
You can't view details of this content, please login or buy subscription here